The Week Ahead: Hom...
Health Care: Drugs
Alimera Sciences Inc. (ALIM: NASDAQ)
$4.18 -0.10 | -2.34%
05/17/13 - 04:00 PM ET
229.25K / 65.10K
Vol / Avg. Vol:4.25 / 4.28
Open / Prev. Close:3.85 - 4.47
Today's Range:1.26 - 5.10
52 Wk Range:172.61%
Performance YTD:TheStreet Rating:
Portfolios with ALIM
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- Userconsidering
- ContributorStocks Under-$10 Moving Hig...
- Contributor5 Biggest Drug-Stock Losers...
- ContributorStocks Under-$10 Setting Up...
- ContributorHot Biotech Trades for Seco...
- Contributor9 Health Care Stocks With 1...
- Contributor10 Pharma Stocks With 100% ...
- Userbiotech
Latest ALIM Headlines from TheStreet
- Ampio's Eye Drug Trial Design Won't Pass FDA Muster 04.02.13 | 09:04 am
- Alimera Sciences' CEO Discusses Q2 2012 Results - Earnings Call Transcript 08.11.12 | 11:08 pm
- Alimera Sciences Reports Second Quarter 2012 Financial Results 08.09.12 | 04:08 pm
- 8 Stocks Under $10 Making Big Moves 04.24.12 | 12:04 pm
- 8 Stocks Under $10 Moving Higher 03.27.12 | 02:03 pm
- 5 Biggest Drug-Stock Losers of 2011 12.21.11 | 06:12 am
- 5 Stocks Under $10 Set to Soar 12.08.11 | 02:12 pm
- Biotech Calendar: Key Dates for November 11.01.11 | 10:11 am
- 9 Health Care Stocks With 100% Buy Ratings 05.05.11 | 04:05 pm
- Alimera Sciences To Present At March Conferences 02.24.11 | 06:02 am
Press Releases for ALIM
- Alimera Sciences To Release First Quarter Fiscal Year 2013 Financial Results - PR Newswire 05.03.13 | 01:05 pm
- Alimera Sciences To Release Fourth Quarter And Fiscal Year 2012 Financial Results - PR Newswire 03.11.13 | 01:03 pm
- Alimera Sciences Participating In Credit Suisse London One-on-One Healthcare Conference - PR Newswire 02.20.13 | 07:02 am
- Alimera Sciences To Release Third Quarter Fiscal Year 2012 Financial Results - PR Newswire 10.22.12 | 11:10 am
- U.K.'s National Institute For Health And Clinical Evidence Accepts Alimera Sciences' ILUVIEN® Subgroup Data For Review - PR Newswire 09.05.12 | 08:09 am
- Alimera Sciences' ILUVIEN® Receives Marketing Authorization In Germany For The Treatment Of Chronic Diabetic Macular Edema - PR Newswire 07.26.12 | 07:07 am
Partner Headlines for ALIM
- After-Hours Earnings Report for March 21, 2013 : NKE, SLW, MU, TIBX, RUE, NWY, ALIM - NASDAQ 03.21.13 | 06:03 pm
- Psivida Licensee Set For European Launch By Year's End - Seeking Alpha 04.11.12 | 09:04 am
- Alimera Sciences: An Upcoming Catalyst Should Make For A Nice Stock Gain - Seeking Alpha 03.26.12 | 09:03 am
- Oppenheimer Increases Alimera Sciences PT - Benzinga 02.28.12 | 04:02 pm
- 6 Oversold Stocks With Insider Buying - Seeking Alpha 09.08.11 | 09:09 am
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 07.05.11 | 09:07 am
- Analyzing Seeking Alpha's Top Gainers and Losers Using Levered Free Cash Flow - Seeking Alpha 04.15.11 | 09:04 am
- 6 Cash Rich Biotech Stocks With Catalysts - Seeking Alpha 04.08.11 | 08:04 am
- Low-Priced Biotech Stocks With Insider Buying - Seeking Alpha 03.18.11 | 06:03 pm
- Zacks #5 Rank Additions for Monday - Tale of the Tape - Zacks 02.14.11 | 09:02 am
